Sotera Health CoSHC +2.43%74 EBITDA Margin % is 38.63% as of Mar. 2026, which is 1% below its 10-year median of 39.06. GuruFocus rates SHC with a GF Score™ of 74/100 and a GF Value™ of $16.31 (Fairly Valued). The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Sotera Health Co ranks better than 97.55% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sotera Health Co's EBITDA for the
three
months ended in Mar. 2026 was $108 Mil. Sotera Health Co's Revenue for the
three
months ended in Mar. 2026 was $280 Mil. Therefore, Sotera Health Co's EBITDA margin for the quarter that ended in Mar. 2026 was 38.63%.
Sotera Health Co (NAS:SHC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sotera Health Co EBITDA Margin % Related Terms
Sotera Health Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHC vs BLLN, RDNT, TWST: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Sotera Health Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotera Health Co (SHC) has a EBITDA Margin % of 38.63% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sotera Health Co and its competitors. This is near median its historical median of 39.06. According to the industry distribution chart, Sotera Health Co ranks #5 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 2.5%.
Is Sotera Health Co's EBITDA Margin % too high?
Sotera Health Co's current EBITDA Margin % of 38.63% is near median its 10-year median of 39.06. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Sotera Health Co's value of 38.63% is 642.9% above this industry median. Based on the distribution chart, Sotera Health Co ranks #5 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sotera Health Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's EBITDA Margin % compare to BLLN and RDNT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #5 out of 204 companies for EBITDA Margin %. This places Sotera Health Co in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Sotera Health Co's value of 38.63% is 642.9% above this benchmark. While the company's 10-year median is 39.06 vs. the industry median of 5.20, Sotera Health Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotera Health Co's current EBITDA Margin % of 38.63% is 642.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sotera Health Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current EBITDA Margin % is 38.63%, which is near median its own 10-year median of 39.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.31, compared to a current price of $17.10 — trading 4.8% above its estimated fair value. The current EBITDA Margin % is 38.63%, which is near median its 10-year median of 39.06 and 642.9% above the Medical Diagnostics & Research industry median of 5.20. Sotera Health Co's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sotera Health Co (SHC), the current EBITDA Margin % is 38.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $17.10 is trading 4.8% above its estimated GF Value™ of $16.31.
GuruFocus considers Sotera Health Co to be Fairly Valued.
Key valuation signals for SHC:
EBITDA Margin %: 38.63% (near median its 10-year median of 39.06)
GF Value™: $16.31 vs. price of $17.10 (4.8% above fair value)
Industry Position: 642.9% above the Medical Diagnostics & Research median (#5 of 204)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
74GF Score
Get the complete analysis for SHC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
